2024-12-19 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a global healthcare company producing a wide range of medical devices, pharmaceuticals, and consumer health products, significantly underperformed the S&P 500 (VOO) over the measured period.  The cumulative return for JNJ is 23.74%, while the S&P 500 achieved 114.36%. This represents a difference of -90.6 percentage points.  The relative divergence of -90.6 places JNJ at the 7th percentile of its historical range relative to the S&P 500, indicating substantial underperformance.


**2. Recent Price Movement:**

* **Closing Price:** $144.75
* **5-day Moving Average:** $145.57
* **20-day Moving Average:** $150.47
* **60-day Moving Average:** $155.83

The current price is below all three moving averages, suggesting a downward trend in the short to medium term.

**3. Technical Indicators and Expected Return:**

* **RSI (18.88):** Indicates the stock is in oversold territory, potentially suggesting a bounce is possible.
* **PPO (-0.30):** Shows a bearish signal, aligning with the negative price trend.
* **20-day Relative Divergence (+7.0):** Suggests a recent short-term uptrend, although this is minor compared to the longer-term downtrend.
* **Expected Return (0.0%):**  The provided data shows a zero expected return relative to the S&P 500 for long-term (2+ years) investment. This suggests the model doesn't predict outperformance of the S&P 500 for JNJ.  Given the current price is below various moving averages and the low RSI, there's a possibility of short-term upward movement, but the long-term prospects relative to the S&P 500 are considered neutral at best based on this data.  A 0.0% expected return means the model doesn't predict JNJ significantly outperforming or underperforming VOO over the long term.

**4. Recent Earnings Analysis:**

The provided earnings data shows mixed results:

* **EPS:** Fluctuated significantly across quarters, with a considerable drop from $1.95 in Q2 2024 to $1.12 in Q3 2024. This needs further investigation to determine the cause.  The exceptionally high EPS of $10.32 in Q4 2023 is an outlier and requires context beyond what's provided to understand the reason for this significant increase.
* **Revenue:** Remained relatively stable, hovering around $21-22.5 billion over the past five quarters, indicating consistent revenue generation. However, there is no clear growth trend visible.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is fairly consistent, with profit margins generally high (68-70%), suggesting strong profitability.
* **Capital and Profitability:** Equity fluctuates, and ROE shows inconsistency. The extremely high ROE of 36.54% in Q3 2023 is a significant outlier and needs further context.

**6. News and Recent Issues:**

This section requires information not provided in your prompt.  To complete this section, please provide recent news articles or press releases related to JNJ.  Similarly, information on recent market outlook and analyst opinions is needed to fully address this point.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 recently. While the company demonstrates consistent revenue and high profit margins, recent EPS results are volatile, and overall financial data requires deeper analysis to understand the causes behind the large fluctuations. Technical indicators suggest the stock is currently oversold, potentially hinting at short-term upward potential. However, the lack of clear revenue growth, inconsistent ROE, and the 0.0% expected return relative to the S&P 500 raise concerns about its long-term prospects.  Further investigation into the reasons for the significant EPS and ROE fluctuations in Q4 2023 and Q3 2024 is crucial.  Missing news and analyst opinions prevent a complete evaluation of the current market sentiment and future prospects for the company.


**8. Disclaimer:** This analysis is based solely on the limited data provided. It is not financial advice, and further investigation and consideration of additional factors are strongly recommended before making any investment decisions.  Consult with a financial advisor for personalized guidance.
